Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds.

Robbrecht, D G J; Buck, S A J; de Wit, R

Robbrecht, D G J; Buck, S A J; de Wit, R.

Affiliation

Robbrecht DGJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Buck SAJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
de Wit R; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Electronic address: r.dewit@erasmusmc.nl.

Ann Oncol ; 32(7): 831-832, 2021 07.

Article in En | MEDLINE | ID: mdl-33930524

Subject(s)

Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms/diagnosis; Prostatic Neoplasms/drug therapy; Taxoids; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Prostatic Neoplasms / Prostatic Neoplasms, Castration-Resistant Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans / Male Language: En Year: 2021 Type: Article

Fulltext

XML

PubMed Links

Search on Google